Lenalidomide in myelodysplastic syndromes: where do we go from here?

abstract：:High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achi...

journal_title：Current hematologic malignancy reports

authors： Kumar S

更新日期：2007-05-01 00:00:00

abstract：PURPOSE OF REVIEW:This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS:Over the last decade, the routine use of HCT as consolidative t...

journal_title：Current hematologic malignancy reports

authors： Hunter BD,Chen YB

更新日期：2020-02-01 00:00:00

abstract：:Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrat...

journal_title：Current hematologic malignancy reports

authors： Choi J,Foss F

更新日期：2007-10-01 00:00:00

abstract：:A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...

journal_title：Current hematologic malignancy reports

authors： Finazzi G,De Stefano V,Barbui T

更新日期：2013-12-01 00:00:00

abstract：:The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors,...

journal_title：Current hematologic malignancy reports

authors： Pinnix CC,Andraos TY,Milgrom S,Fanale MA

更新日期：2017-06-01 00:00:00

abstract：:Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...

journal_title：Current hematologic malignancy reports

authors： Chung CG,Poligone B

更新日期：2015-12-01 00:00:00

abstract：:Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...

journal_title：Current hematologic malignancy reports

authors： Selimoglu-Buet D,Solary E

更新日期：2014-12-01 00:00:00

abstract：:Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...

journal_title：Current hematologic malignancy reports

authors： Jacobson NB,Parekh N,Kalaycio M

更新日期：2006-09-01 00:00:00

abstract：:In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment. The most useful currently available MRD assays are polymerase chain reaction amplification of fusion transcripts and rearranged antigen-receptor genes and flow cytometric detection of ab...

journal_title：Current hematologic malignancy reports

authors： Campana D

更新日期：2008-07-01 00:00:00

abstract：:Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...

journal_title：Current hematologic malignancy reports

authors： Dabrowska-Iwanicka A,Walewski JA

更新日期：2014-09-01 00:00:00

abstract：:Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criter...

journal_title：Current hematologic malignancy reports

authors： Steensma DP

更新日期：2012-12-01 00:00:00

abstract：:Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18...

journal_title：Current hematologic malignancy reports

authors： Zinzani PL

更新日期：2011-12-01 00:00:00

abstract：PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...

journal_title：Current hematologic malignancy reports

authors： Hakki M

更新日期：2020-04-01 00:00:00

abstract：:The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...

journal_title：Current hematologic malignancy reports

authors： Hebb J,Kohrt H

更新日期：2015-12-01 00:00:00

abstract：:Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...

journal_title：Current hematologic malignancy reports

authors： Bradstock K

更新日期：2006-06-01 00:00:00

abstract：:The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...

journal_title：Current hematologic malignancy reports

authors： Roberts DA,Steensma DP

更新日期：2015-09-01 00:00:00

abstract：PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...

journal_title：Current hematologic malignancy reports

authors： Kennedy JA,Hobbs G

更新日期：2018-06-01 00:00:00

abstract：:Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...

journal_title：Current hematologic malignancy reports

authors： Faderl S,Wierda W,Keating MJ

更新日期：2006-12-01 00:00:00

abstract：:BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive ...

journal_title：Current hematologic malignancy reports

authors： Scherber RM,Geyer HL,Mesa RA

更新日期：2014-12-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...

journal_title：Current hematologic malignancy reports

authors： Kahl BS

更新日期：2009-10-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. Th...

journal_title：Current hematologic malignancy reports

authors： Gergis U,Wissa U

更新日期：2010-01-01 00:00:00

abstract：PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...

journal_title：Current hematologic malignancy reports

authors： Bangerter LR,Griffin JM,Langer S,Hasan B,Kim WS,Murad MH,Khera N

更新日期：2018-06-01 00:00:00

abstract：:Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

journal_title：Current hematologic malignancy reports

authors： Buckley SA,Walter RB

更新日期：2015-06-01 00:00:00

abstract：:Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...

journal_title：Current hematologic malignancy reports

authors： Forstpointner R,Dreyling M

更新日期：2011-12-01 00:00:00

abstract：:Morphologic dysplasia is an important factor in diagnosis of myelodysplastic syndrome (MDS). However, the role of dysplasia is changing as new molecular genetic and genomic technologies take a more prominent place in diagnosis. This review discusses the role of morphology in the diagnosis of MDS and its interactions w...

journal_title：Current hematologic malignancy reports

authors： Shaver AC,Seegmiller AC

更新日期：2017-10-01 00:00:00

abstract：:Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...

journal_title：Current hematologic malignancy reports

authors： Pieters R

更新日期：2009-07-01 00:00:00

abstract：:Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL c...

journal_title：Current hematologic malignancy reports

authors： Portell CA,Advani AS

更新日期：2012-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...

journal_title：Current hematologic malignancy reports

authors： Radakovich N,Nagy M,Nazha A

更新日期：2020-06-01 00:00:00

abstract：PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...

journal_title：Current hematologic malignancy reports

authors： Patel AA,Odenike O

更新日期：2020-12-01 00:00:00

abstract：PURPOSE OF REVIEW:To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response. RECENT FINDINGS:Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognosti...

journal_title：Current hematologic malignancy reports

authors： Mina AA,Stein B

更新日期：2019-06-01 00:00:00